Text Size

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT00058994
First received: April 15, 2003
Last updated: November 28, 2012
Last verified: August 2008
History of Changes
  Purpose

The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.


Condition Intervention Phase
Macular Degeneration
Maculopathy, Age-Related
 Drug: anecortave acetate
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-related Macular Degeneration

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Alcon Research:

Study Start Date: March 2003
Study Completion Date: November 2006
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Patients at least 50 years of age, of any race, and either sex with a clinical diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00058994

Locations
United States, Texas
South America
Fort Worth, Texas, United States
Sponsors and Collaborators
Alcon Research
Investigators
Principal Investigator: Alcon Investigators Alcon Research
  More Information

No publications provided

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT00058994     History of Changes
Other Study ID Numbers: C-02-29
Study First Received: April 15, 2003
Last Updated: November 28, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Alcon Research:
AMD
anecortave acetate
wet AMD
age-related macular degeneration
Macular Degeneration
 Maculopathy, Age-Related
Age-Related Maculopathies
Age-Related Maculopathy
Maculopathies, Age-Related

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Choroidal Neovascularization
Retinal Degeneration
Retinal Diseases
Eye Diseases
 Choroid Diseases
Uveal Diseases
Neovascularization, Pathologic
Metaplasia
Pathologic Processes

ClinicalTrials.gov processed this record on May 21, 2013